These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 23806241)
21. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049 [TBL] [Abstract][Full Text] [Related]
22. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses]. Westra TA; Daemen T; Postma MJ; Wilschut JC Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733 [TBL] [Abstract][Full Text] [Related]
23. Comprehensive control of human papillomavirus infections and related diseases. Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S; Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745 [TBL] [Abstract][Full Text] [Related]
24. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574 [TBL] [Abstract][Full Text] [Related]
25. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J BMJ; 2015 May; 350():h2016. PubMed ID: 25985328 [TBL] [Abstract][Full Text] [Related]
26. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146 [TBL] [Abstract][Full Text] [Related]
28. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES]. Malinova M Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767 [TBL] [Abstract][Full Text] [Related]
29. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. Cody P; Tobe K; Abe M; Elbasha EH BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188 [TBL] [Abstract][Full Text] [Related]
30. Beyond cervical cancer: burden of other HPV-related cancers among men and women. Chaturvedi AK J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840 [TBL] [Abstract][Full Text] [Related]
31. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913 [TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Zechmeister I; Blasio BF; Garnett G; Neilson AR; Siebert U Vaccine; 2009 Aug; 27(37):5133-41. PubMed ID: 19567244 [TBL] [Abstract][Full Text] [Related]
33. Health and economic implications of HPV vaccination in the United States. Kim JJ; Goldie SJ N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of human papilloma virus vaccination in Iceland. Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074 [TBL] [Abstract][Full Text] [Related]
35. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review. Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299 [TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913 [TBL] [Abstract][Full Text] [Related]
38. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina. Borracci RA; Segal SV; Méndez JH Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924 [TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of male HPV vaccination in the United States. Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Simons JJM; Vida N; Westra TA; Postma MJ Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]